Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.74 USD
Change Today +0.15 / 2.68%
Volume 125.1K
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

David M. Pernock

Chairman, Chief Executive Officer and President,Fibrocell Science, Inc.
AgeTotal Calculated CompensationThis person is connected to 93 board members in 5 different organizations across 3 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. David M. Pernock has been the Chairman of the Board and Chief Executive Officer of Fibrocell Science, Inc. since September 2009 and February 1, 2010 respectively and also serves as its President. Mr. Pernock served as the Senior Vice President of U.S., pharmaceuticals/vaccines & Biologics, Specialty Businesses - Philadelphia for GlaxoSmithKline P.L.C. He served in a variety of executive capacities for GlaxoSmithKline (GSK) from 1994 to 2009, including Senior Vice ...

Read Full Background

Corporate Headquarters*

405 Eagleview Boulevard
Exton, Pennsylvania 19341

United States

Phone: 484-713-6000
Fax: --

Board Members Memberships*

Chairman, Chief Executive Officer and President


Arizona State University-Tempe

Other Affiliations*

Annual Compensation*

Total Annual Compensation$490,000

Stock Options*

Exercisable Options515,500
Unexercisable Options687,500
Total Number of Options1,203,000

Total Compensation*

Total Annual Cash Compensation$490,000
Total Short Term Compensation$490,000
Total Calculated Compensation$490,000
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FCSC:US $5.74 USD +0.15


Michael D. West Ph.D.Chief Executive Officer, President and Director
BioTime, Inc.
Marc H. Hedrick M.D.Chief Executive Officer, President, Director and Member of Executive Committee
Cytori Therapeutics, Inc.
Edward O. Lanphier IIFounder, Chief Executive Officer, President, Director and Member of Clinical Review Committee
Sangamo Biosciences Inc.
Paul K. Wotton Ph.D.Chief Executive Officer, President and Director
Ocata Therapeutics, Inc.
Keith Murphy Chairman, Chief Executive Officer, President, Member of Audit Committee and Member of Science & Technology Committee
Organovo Holdings, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FIBROCELL SCIENCE INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at